Laboratory research is entering a new phase of AI-assisted discovery as companies move beyond single-model tools toward agent-based systems designed to support end-to-end scientific reasoning. In recent papers published in Nature, researchers from Google DeepMind and FutureHouse describe two systems, Co-Scientist and Robin, that generate hypotheses, design experiments, and analyze scientific literature to support research workflows.
These tools reflect a broader shift in lab automation, where AI systems are increasingly structured as coordinated agents rather than single, prompt-driven models. Each agent performs a specialized function, and together they contribute to hypothesis generation and research planning tasks that typically require significant human time and expertise.
At a high level, both systems aim to help scientists identify promising research directions earlier in the discovery pipeline, particularly in areas such as drug repurposing.
Multi-agent systems in research workflows
The systems described in the Nature papers rely on multi-agent architectures. Instead of relying on a single model to complete a task, multiple specialized agents collaborate on different parts of the research process, such as literature review, hypothesis generation, and evaluation.
This approach is designed to break down complex scientific reasoning tasks into smaller components that can be processed and refined iteratively. The goal is to support researchers by accelerating early-stage ideation and analysis before experimental validation begins.
Robin supports end-to-end hypothesis generation
Robin, developed by FutureHouse, is designed to generate hypotheses, propose experiments, and analyze results in a closed research loop focused on drug repurposing.
According to a C&EN report, the system includes three agents: two that conduct literature review and one that analyzes experimental data. A researcher provides a disease target, and Robin generates potential treatment hypotheses along with suggested experiments to test them.
In a demonstration focused on dry age-related macular degeneration, Robin reviewed relevant literature, proposed FDA-approved drugs for repurposing, and outlined experimental approaches such as RNA sequencing and flow cytometry to evaluate their effects. Researchers then conducted the experiments and fed the results back into the system for analysis and follow-up suggestions.
The tool is designed to support iterative cycles of hypothesis generation and validation, although experimental execution still requires human-led laboratory work.
Co-Scientist structures scientific reasoning tasks
Google DeepMind’s Co-Scientist is described as a structured scientific reasoning system that uses multiple agents to review literature, generate hypotheses, and evaluate competing ideas.
The system produces candidate hypotheses based on scientific literature and refines them through internal review and ranking processes. It is intended to help researchers identify promising directions for further study.
In one example described in the Nature publication, researchers applied Co-Scientist to drug repurposing in acute myeloid leukemia. Oncologists reviewed the system’s suggestions, and several proposed compounds were tested in laboratory settings. Some candidates showed activity against leukemia cells in vitro, including compounds previously evaluated in clinical trials.
The system has also been applied to other research problems, including identifying potential targets for liver fibrosis and generating corresponding drug-repurposing hypotheses.
Early applications focus on drug repurposing
Both Robin and Co-Scientist were evaluated in part through drug repurposing use cases, in which existing FDA-approved drugs are assessed for potential new therapeutic applications. Repurposing is often viewed as a practical starting point for AI-driven discovery because it builds on compounds with established safety profiles. However, promising in vitro results still require extensive clinical validation, and many drug candidates fail during human trials.
Advanced Lab Management Certificate
The Advanced Lab Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
Limitations and research context
The developers and researchers cited in the Nature publications emphasize that these tools are designed to assist scientists rather than replace them. AI-generated hypotheses require experimental validation, and biological complexity, including variability in disease models and patient populations, limits the ability of computational systems to fully predict outcomes.
The systems also rely primarily on available datasets, which may constrain the scope of their reasoning.
Despite these limitations, researchers quoted in the C&EN report describe growing interest in integrating agent-based AI into scientific workflows, particularly as part of broader efforts to connect computational tools with automated laboratory systems.
Outlook for laboratory integration
Future agent-based systems could integrate more directly with laboratory automation platforms, creating tighter feedback loops between hypothesis generation, experimentation, and data analysis. While fully autonomous research systems remain theoretical, tools like Robin and Co-Scientist reflect a shift toward AI platforms that can participate in structured scientific workflows rather than functioning solely as standalone analytical tools. For laboratories, the most immediate impact may be faster early-stage research planning, particularly in literature review, hypothesis generation, and experimental prioritization.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
